10X Genomics
7068 Koll Center Parkway
Suite 401
Pleasanton
California
94566
United States
Website: https://www.10xgenomics.com/careers/
Email: recruiting@10xgenomics.com
90 articles with 10X Genomics
-
10x Genomics Reports Third Quarter 2020 Financial Results
11/10/2020
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020 Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundatio
-
10x Genomics to Participate in the Stifel 2020 Healthcare Conference
11/4/2020
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10x Genomics 10x Ge
-
10x Genomics to Report Third Quarter Financial Results on November 10, 2020
10/13/2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: w
-
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
-
10x Genomics Announces Pricing of Upsized Public Offering - Sep 11, 2020
9/11/2020
10x Genomics, Inc. announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions.
-
10x Genomics Announces Launch of a Follow-On Public Offering - Sep 08, 2020
9/8/2020
10x Genomics, Inc. announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company pursuant to a registration statement filed with the Securities and Exchange Commission.
-
10x Genomics Reports Second Quarter 2020 Financial Results
8/11/2020
10x Genomics, Inc. reported financial results for the second quarter ended June 30, 2020.
-
10x Genomics to Participate in the UBS Genomics 2.0 and Medtech Innovations Summit
8/6/2020
10x Genomics announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.
-
10x Genomics Selects First 45 Members for Visium Clinical Translational Research Network
6/17/2020
GSK, Johns Hopkins Medical Institutions, Mass General Cancer Center join global network to accelerate discoveries in COVID-19, oncology, immuno-oncology and neurology
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
-
10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing Pioneering Effort for Safe Workplace Reentry
5/19/2020
Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom screening, and seamless access to remote and in-person care. 10x Genomics is the first of One Medical’s more than 7,000 employer customers to begin executing a multi-pronged,
-
10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee TestingPioneering Effort for Safe Workplace Reentry
5/19/2020
Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom screening, and seamless access to remote and in-person care. 10x Genomics is the first of One Medical’s more than 7,000 employer customers to begin executing a multi-pronged,
-
10x Genomics Reports First Quarter 2020 Financial Results
5/11/2020
10x Genomics, Inc. reported financial results for the quarter ended March 31, 2020.
-
10x Genomics to Present at the BofA Securities 2020 Healthcare Conference
5/5/2020
10x Genomics announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference.
-
10x Genomics to Report First Quarter Financial Results on May 11, 2020
4/24/2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.10
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
-
10x Genomics Provides COVID-19 Business Impact Update and Response
4/9/2020
10x Genomics, provided an update on the actions it is taking to focus its business operations to support critical research in response to the coronavirus pandemic as well as the financial impact.
-
10x Genomics Appoints Kim Popovits to Board of DirectorsFormer Genomic Health CEO brings decades of healthcare experience to Board
4/2/2020
10x Genomics, Inc. announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors.
-
10x Genomics Debuts Range of New Products at AGBTShips Chromium Connect; Unveils Dozen New Applications to Advance Genomics
2/24/2020
PLEASANTON, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced a broad range of new products at the Advances in Genome Biology and Technology (AGBT) General Meeting, as well as new capabilities for existing products. Today’s announcements further 10x Genomics’ commitment to helping researchers see biology at greater resolution and scale, conduct more simultaneous measurements, and have richer context for their work regardless of the size or location
-
10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue GuidanceFull year 2019 revenue growth of 68% over prior year
2/18/2020
10x Genomics, Inc., reported financial results for the fourth quarter and full year ended December 31, 2019.